Drug reference

pamidronate

Bisphosphonate · Antiresorptive agent

BisphosphonateAntiresorptive agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Not yet extracted

Indications

Paget diseasehypercalcemia of malignancyprevention of bone loss in breast cancer and multiple myelomaPaget’s diseaseHypercalcaemia of malignancyBony metastasisHumoral Hypercalcemia of MalignancyHypercalcemia in multiple myelomaPrevent bone-related complications in multiple myeloma

Dosing

Adult: For hypercalcemia, an intravenous infusion of 60 to 90 mg over 4 to 24 h. For prevention of bone loss in breast cancer and multiple myeloma, an intravenous infusion of 60 to 90 mg over 2 to 24 h.

Contraindications

Gastroesophageal reflux
Peptic ulcer
Renal impairment (general BPN contraindications)

Side effects

Common

skin flushingflu-like symptomsmuscle and joint aches and painsnausea and vomitingabdominal discomfortdiarrheaconstipationThrombophlebitis of injected veinBone painFeverLeukopeniaFlu-like reaction (initially due to cytokine release)

Serious